Home › NCT06686693
Intravenous Iron Effects on Performance at High Altitude
Intravenous Iron Prophylaxis for Rapid High Altitude Insertions
Who can join
Ages 18 to 40 · All sexes · Healthy volunteers welcome
Full eligibility criteria
Inclusion Criteria: * Man or woman, age 18-40 years * BMI 18.5-30 kg/m2 * In good health as determined by the Office of Medical Support \& Oversight (OMSO) General Medical Clearance * Passed his/her most recent Army Combat Fitness Test (ACFT) (Military Volunteers Only) or exercises at least 2 times per week and able to complete two mile run in ≤ 21 minutes (Civilian Volunteers) * Willing to not exercise, or drink alcoholic/caffeinated beverages 24 hours prior to each testing session * Willing to not perform any strenuous exercise 36 hours prior to each testing session Exclusion Criteria: * Women who are pregnant or planning to become pregnant during the study * Taking prescription medication, or over-the-counter medications other than contraceptives, unless approved by OMSO \& PI * Taking dietary supplements unless approved by OMSO \& PI * Born at altitudes greater than 2,100 m (7,000 ft) * Living in areas that are more than 1,200 m (4,000 ft) or have traveled to areas that are more than 1,200 m for five days or more within the last 2 months * Prior diagnosis of High Altitude Pulmonary Edema (HAPE) or High Altitude Cerebral Edema (HACE) * Musculoskeletal injuries that compromise the ability to walk/run on a treadmill * Presence of abnormal blood chemicals (hemoglobin S or Sickle Cell Trait) * Hemoglobin concentration: men: Hb \<13.5 g/dL or Hb \>17.7 g/dL; women Hb \<12.5 g/dL or Hb \>15.9 g/dL * Ferritin \< 50 ng/mL or greater than 150 ng/mL * Any history of malignancy * Personal or family history of blood clots * History of thromboembolic disease, hypertension, and known risk factors of cardiovascular disease * Blood donation within 8 weeks of beginning the study * History of seizures * History of inflammatory bowel disease * Any recent (within 4-6 weeks) and or expected history of prolonged periods of immobility or limited activity (including recent or upcoming surgery) * Abnormal PT/PTT test or problems with blood clotting * Any nicotine or recreational drug use (unless quit \> 1 month prior to study orientation) * Presence of respiratory tract infections (\< 1 month prior) * Experience recent cold, coughs, or sinus infections (\< 2 weeks prior) * Allergy to skin adhesive * Evidence of apnea or sleeping disorder * Present condition of alcoholism, use of anabolic steroids, other substance abuse issues * Body mass \<50 kg (110.5 lbs) * History of hyperparathyroidism * History of vitamin D deficiency * History of systemic inflammatory disease (rheumatoid arthritis, lupus erythematosus) * Any drug allergies * History of hypersensitivity reaction * History of asthma * History of kidney or liver disease * Any previous intravenous iron injection
About the study
To compare the effects of IV iron versus placebo (saline) injection on arterial oxygen saturation, submaximal exercise responses, and 2-mile treadmill time-trial performance during acute exposure to hypobaric hypoxia (430 mmHg, simulating \~4800m) assessed 1 and 14 days after treatment.
Primary Hypothesis 1: IV iron treatment will improve arterial oxygen saturation at rest and during exercise in acute hypobaric hypoxia and this effect will persist for 2 weeks
Primary Hypothesis 2) IV iron treatment will improve 2-mile treadmill time trial performance in acute hypobaric hypoxia and this effect will persist for 2 weeks
What is being tested
- Injectafer (drug)
- Placebo (other)
Sponsor: United States Army Research Institute of Environmental Medicine · Participants: 24 · Started: Apr 15, 2022
Contact the study team
- Roy Salgado, PhD · Phone: 508-206-2375
Official record on ClinicalTrials.gov — NCT06686693
Locations in the U.S.
| Massachusetts | USARIEM, Natick |
From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.